Obu Health Tirzepatide Review: Plans, Care and Cancellation

Obu Health advertises compounded tirzepatide at $239 monthly and lists longer subscription options. The named product page says consultation, ongoing care, dose adjustments and expedited shipping are included, with no hidden membership fee and the same price at every dose. Confirm the prescription and complete selected agreement rather than assuming the monthly headline describes every payment.⁴

The practical comparison is the medication supplied, the amount collected, access to a clinician and what cancellation changes. A price card or certification badge does not independently verify the preparation, your assigned provider or the outcome of treatment.

Read the plan label and payment together

The named product page shows a $239 monthly card, a $589 three-month card and a $1,074 six-month card. It also exposes a twelve-month selector without a separately readable twelve-month price in the inspected page. These are advertised plan labels and amounts, not an accepted invoice or proof of when every installment is collected.⁴

Before choosing a longer option, obtain its full first charge, any installments, renewal period and remaining obligation if you cancel. Confirm the prescribed dose, concentration, total quantity and shipping schedule. Three months on a plan card does not independently prove three vials arrive together or that every supplied dose has the same concentration.

The product’s same-price-at-every-dose claim is different from a published prescription quantity. It also should not turn the branded-drug research quoted in its marketing into evidence that a particular compounded preparation produces the same result.⁴

Intake, live contact and follow-up

The homepage describes a questionnaire, clinician review and delivery if eligible. Its board-certification language is the company’s claim, not independent verification of the practitioner who will evaluate you.³

The general FAQ describes feedback in approximately 24 hours, with video or live chat required in some states. The homepage describes possible video or telephone contact instead. Confirm the actual consultation method for your location; neither description establishes guaranteed approval or medication delivery within a day.^3,5

Ask how ongoing dose questions are handled, whether another assessment is needed and what to do if a live or in-person evaluation is appropriate. The inclusion of ongoing care does not establish a guaranteed response time or emergency coverage. The Terms expressly leave treatment and prescription decisions to the provider.⁶

Charging, cancellation and an existing order

The FAQ says medication is billed when shipped. The product says cancellation is available through the patient portal and does not affect orders already shipped. Read that alongside the returns policy, which places ordinary finality after the payment method is charged and the package is handed to the carrier.^4,5,7

The returns page allows subscription cancellation before products ship, while excluding returns of dispensed prescriptions. It asks patients to contact support for damage or transit loss and says a lost package will be reshipped after efforts to locate or redirect it. Its thirty-day return allowance concerns unopened nonprescription products, not tirzepatide.⁷

These pages do not clearly settle the financial result of clinical denial, an already-charged but unshipped order, or an unused portion of a longer subscription. Ask for those rules and the next renewal amount and date before paying. Do not convert cancel-anytime language into a promise that every prior charge or remaining installment disappears.

The returns page also contains generic wording that it does not ship refrigerated products. That is not preparation-specific evidence of tirzepatide stability. Ask the actual pharmacy for storage requirements, transit limits and what to do after a temperature excursion.⁷

Clinical network, pharmacies and geography

The general FAQ names MD Integrations as the provider network and lists Manifest Pharmacy in South Carolina and RX Compounding Store in Florida as possible pharmacies, depending on the therapy. This is a published network list, not confirmation of your dispenser or an independent licensing inspection.⁵

The named product describes patient-specific compounding under Section 503A. Confirm which facility prepares your medicine and its authority to dispense where you are receiving care. A platform’s general pharmacy description does not verify every facility’s classification, testing or the quality of a particular vial.⁴

Eligibility is U.S.-based and therapy- and state-dependent. The FAQ gives examples of physicians for certain states, but that does not establish that every treatment is available nationwide. Obtain the treating practitioner’s name and the actual route of care for your location.⁵

The Terms allow requesting a chosen pharmacy before completing the order. They also prohibit submitting telemedicine-service claims to Medicare or another public or private payor. A separate pharmacy purchase can have its own price; neither local dispensing nor an HSA/FSA payment establishes reimbursement eligibility for the clinical service.⁶

Evidence and our assessment

Compounded tirzepatide is not an FDA-approved finished drug. Trials of approved injections in SURMOUNT-1 and SURMOUNT-5 do not verify Obu’s service outcomes, preparation or dose-specific performance.^1,2 Our compounding guide and evidence guide explain the distinction.

Obu publishes a named offer, included clinical care, a provider network and prescription-specific return boundaries. Its useful comparison requires confirming the longer-plan financial commitment, response expectations and actual prescription. A displayed certification image should not substitute for checking the assigned clinician and pharmacy.

Compare Ondra Health, NewSelf, Onyx Weight Loss and the provider comparison under each program’s own agreement. Prepare clinical questions with the side-effect guide, gallbladder discussion and thyroid warning explanation.